Utilisation of the ESMO-MCBS in practice of HTA

C. Wild, N. Grössmann, P. V. Bonanno, A. Bucsics, J. Furst, K. Garuoliene, B. Godman, J. Gulbinovič, J. Jones, M. K. Pomorski, R. Emprechtinger

Research output: Contribution to journalArticle

23 Citations (Scopus)
23 Downloads (Pure)

Abstract

It is highly appreciated that the European Society of Medical Oncology has developed a system to assess new oncologic compounds according to their value to patients. Consequently, offering decision-support to those who either want to use the new cancer therapies in clinical practice but cannot keep up-to-date with all therapy options or, alternatively, to those who have to decide whether or not to fund new oncology medicines or exclude from reimbursement due to their low value. This is particularly important with ever-rising prices for new oncology medicines which have increased up to ten fold in recent years.
Original languageEnglish
Pages (from-to)2134-2136
Number of pages3
JournalAnnals of Oncology
Volume27
Issue number11
Early online date8 Aug 2016
DOIs
Publication statusPublished - 30 Nov 2016

Keywords

  • oncology
  • cancer therapies
  • clinical practice
  • oncology medicines

Cite this

Wild, C., Grössmann, N., Bonanno, P. V., Bucsics, A., Furst, J., Garuoliene, K., Godman, B., Gulbinovič, J., Jones, J., Pomorski, M. K., & Emprechtinger, R. (2016). Utilisation of the ESMO-MCBS in practice of HTA. Annals of Oncology, 27(11), 2134-2136. https://doi.org/10.1093/annonc/mdw297